Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $70,055.70 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,343 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70. Following the completion of the transaction, the insider now directly owns 165,254 shares in the company, valued at approximately $4,941,094.60. This represents a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.41, for a total transaction of $47,738.99.
• On Tuesday, September 17th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.50, for a total value of $38,593.50.
• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total value of $34,354.25.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $30.34 on Friday. The stock’s fifty day simple moving average is $21.42 and its 200 day simple moving average is $19.65. Hims & Hers Health, Inc. has a one year low of $8.09 and a one year high of $35.02. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of 68.96 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.04) EPS. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the last quarter. Quest Partners LLC increased its position in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares in the last quarter. CWM LLC raised its stake in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the last quarter. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health during the second quarter worth approximately $111,000. Finally, Quarry LP grew its stake in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, TD Cowen reaffirmed a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.